0000899243-22-035451.txt : 20221109
0000899243-22-035451.hdr.sgml : 20221109
20221109170511
ACCESSION NUMBER: 0000899243-22-035451
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221107
FILED AS OF DATE: 20221109
DATE AS OF CHANGE: 20221109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Subramaniam Somu
CENTRAL INDEX KEY: 0001508910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40928
FILM NUMBER: 221373600
MAIL ADDRESS:
STREET 1: C/O ICAD INC
STREET 2: 98 SPIT BROOK ROAD SUITE 100
CITY: NASHUA
STATE: NH
ZIP: 03062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ventyx Biosciences, Inc.
CENTRAL INDEX KEY: 0001851194
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832996852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: (858) 945-2393
MAIL ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-07
0
0001851194
Ventyx Biosciences, Inc.
VTYX
0001508910
Subramaniam Somu
C/O VENTYX BIOSCIENCES, INC., 662
ENCINITAS BLVD, SUITE 250
ENCINITAS
CA
92024
1
0
1
0
Common Stock
2022-11-07
4
S
0
3935
29.0794
D
16888593
I
See Footnotes
Represents the weighted average share price of an aggregate total of 3,935 shares sold in the price range of $29.00 to $29.20. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Consists of (i) 5,873,225 shares held by NSV Investments I, LP, (ii) 2,295,172 shares held by NSV Master Limited Partnership II, LP, (iii) 2,023,131 shares held by NSV 2019 Opportunities Fund, LP, (iv) 1,760,420 shares held by NSV 2018 New Horizons Fund, LP, (v) 1,323,264 shares held by Life & Tech, (vi) 1,179,921 shares held by NSV Investments III, LP, (vii) 998,099 shares held by NSV Investments II, LP, (viii) 434,423 shares held by New Science Ventures, LLC, (ix) 272,484 shares held by NSV Growth Opportunities Fund, LP, (x) 213,533 shares held by New Science Ventures Fund III, LP, (xi) 187,679 shares held by NSV 2017 Opportunities Fund, LP, (xii) 130,872 shares held by NSV 2018 Opportunities Fund, LP, (xiii) 101,221 shares held by NSV 2016 Opportunities Fund, LP, (xiv) 67,314 shares held by New Science Ventures Fund III (Offshore), LP, and (xv) 27,835 shares held by NSV 2016 Opportunities Fund (Offshore), LP, collectively the NSV funds.
NSV Partners III, LP, is the general partner of NSV 2018 New Horizons Fund LP, NSV Investments I, LP, NSV 2018 Opportunities Fund, LP, NSV 2019 Opportunities Fund, LP, NSV Growth Opportunities Fund, LP, NSV Investments III, LP, and NSV Investments II, LP. NSV Partners II, LLC, is the general partner of New Science Ventures Fund III, LP, New Science Ventures Fund III (Offshore), LP, NSV 2016 Opportunities Fund, LP, NSV 2016 Opportunities Fund (Offshore), LP, NSV 2017 Opportunities Fund, LP, and NSV Master Limited Partnership II, LP.
the Reporting Person is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares held by each entity of which NSV Partners III, LP is general partner. The Reporting Person disclaims beneficial ownership over the shares held by each of the NSV funds, except to the extent of his pecuniary interest therein. The Reporting Person is the majority member and managing member NSV Partners II, LLC, and may be deemed to have voting and dispositive power over the shares held by each entity of which NSV Partners II, LLC is general partner.
/s/ Christopher Krueger, as Attorney-in-Fact
2022-11-09